MediSieve, an
award-winning start-up that manufactures a revolutionary life-saving blood
filtration device, has recently welcomed William Twigger as their new Product
Engineer.
Joining the three-person Product Development
team at an exciting time of development, Twigger is poised to bring his wealth
of experience to furthering the innovation of MediSieve by taking
responsibility for the engineering aspects of MediSeive’s product development.
Graduating with a BA honours in Metallurgy and
Material Science in 2010 from the University of Birmingham, Twigger went on to
have a successful career in the medical product engineering sector.
George Frodsham, CEO of MediSieve, commented on
Twigger’s recent appointment: "It’s really great to have Will working with
us, and it’s another exciting development for the company, which is rapidly growing."
"William brings a wealth of engineering
knowledge to the company and we’re all delighted to welcome him to the team."
As the Design Control Engineer at Baxter,
ApaTech, from 2016 to 2017, Twigger was an instrumental part of the company’s
product manufacturing and engineering design. Developing class three medical
devices, which are used to substitute bone as part of surgical procedures, the
company is integral to the success of a number of procedures, such as hip
replacements.
Before his tenure at Baxter, ApaTech, Twigger
was First Water’s Senior Development Engineer. A successful biomaterials company,
First Water have a focus on the research, development and manufacture of wound
care products used to treat chronic skin conditions. Twigger was directly
responsible for updating key documents, such as user requirements, risk files,
design inputs and traceability matrices, in order to remediate before an FDA
audit.
Of his new appointment, Twigger said, "I’m
incredibly excited to be joining such an exciting start-up, and to be working
with such a great team."
"It’s a great opportunity for me and I’m
confident that my experience will help drive continued innovation at the
company."
MediSieve is developing a revolutionary device
used to magnetically filter blood. Similar to dialysis, the patient’s blood is
circulated through an external loop in order to remove any disease-causing
particles or cells. Unlike dialysis, MediSieve uses antibody-coated magnetic particles
to target and remove specific components, providing a flexible, adaptable
platform technology to enable new treatments for a wide range of different
diseases.
MediSieve can be used alongside drug therapy
treatments in the treatment of malaria, leukaemia and sepsis, removing
different specific targets in each case, such as pathogens, malaria-infected
cells or circulating leukaemia cells.
Progressing to clinical trials in 2018, the
MediSieve team is constantly working on ways to broaden the application of the
device and research is ongoing.
For
editorial enquiries, contact 0131 357 8977 or email pr@redheadpr.co.uk
Ends
Follow
redheadPR on Twitter and like them
on Facebook
Visit www.redheadpr.co.uk
Find
out more about founder and managing director, Sara Tye